




































































1 Primary Resistance Mechanism of the Canine Distemper Virus 
2 Fusion Protein against a Small-Molecule Membrane Fusion Inhibitor 
3
4
5 David Kalbermatter1#, Neeta Shrestha2#, Nadine Ader-Ebert3#, Michael Herren2, 
6 Pascal Moll2, Richard K. Plemper4, Karl-Heinz Altmann5, Johannes P. 
7 Langedijk6, Flavio Gall7, Urs Lindenmann7, Rainer Riedl7, Dimitrios Fotiadis1 
8 and Philippe Plattet2*
9
10 1 Institute of Biochemistry and Molecular Medicine, and Swiss National Centre of 
11 Competence in Research (NCCR) TransCure, University of Bern, CH-3012 Bern, 
12 Switzerland.
13 2 Division of Experimental and Clinical Research, Vetsuisse Faculty, University of Bern, CH-
14 3001 Bern, Switzerland.
15 3 Institute of Virology and Immunology, Bern and Mittelhäusern, Switzerland
16 4 Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA
17 5 Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, 
18 ETH Zurich, Zurich, Switzerland
19 6 Janssen Infectious Diseases and Vaccines, Leiden, Netherlands
20 7 Institute of Chemistry and Biotechnology, Center for Organic and Medicinal Chemistry, 
21 Zurich University of Applied Sciences (ZHAW), Einsiedlerstrasse 31, CH-8820 Wädenswil, 
22 Switzerland
23
24 # contributed equally to this work
25
26 * To whom correspondence should be addressed, Bremgartenstrasse 109a, 3001 Bern, 





32 Running Title: 3G-dependent prefusion CDV F stabilization
33 Keywords: fusion inhibitors, fusion protein, head-stalk interface, Morbillivirus cell entry, 






























































36 Morbilliviruses (e.g. measles virus [MeV] or canine distemper virus [CDV]) employ the 
37 attachment (H) and fusion (F) envelope glycoproteins for cell entry. H protein engagement to 
38 a cognate receptor eventually leads to F-triggering. Upon activation, F proteins transit from a 
39 prefusion to a postfusion conformation; a refolding process that is associated with membrane 
40 merging. Small-molecule morbilliviral fusion inhibitors such as the compound 3G (a chemical 
41 analog in the AS-48 class) were previously generated and mechanistic studies revealed a 
42 stabilizing effect on morbilliviral prefusion F trimers. Here, we aimed at designing 3G-
43 resistant CDV F mutants by introducing single cysteine residues at hydrophobic core 
44 positions of the helical stalk region. Covalently-linked F dimers were generated, which 
45 highlighted substantial conformational flexibility within the stalk to achieve those irregular F 
46 conformations. Our findings demonstrate that “top-stalk” CDV F cysteine mutants (F-V571C 
47 and F-L575C) remained functional and gained resistance to 3G. Conversely, although not all 
48 “bottom-stalk” F cysteine variants preserved proper bioactivity, those that remained 
49 functional exhibited 3G-sensitivity. According to the recently determined prefusion MeV F 
50 trimer/AS-48 co-crystal structure, CDV residues F-V571 and F-L575 may directly interact 
51 with 3G. A combination of conformation-specific anti-F antibodies and low-resolution electron 
52 microscopy structural analyses confirmed that 3G lost its stabilizing effect on “top-stalk” F 
53 cysteine mutants thus suggesting a primary resistance mechanism. Overall, our data suggest 
54 that the fusion inhibitor 3G stabilizes prefusion CDV F trimers by docking at the top of the 
































































59 Measles is a vaccine preventable human disease caused by the measles virus (MeV). 
60 MeV is an enveloped RNA virus which belongs to the genus Morbillivirus in the family 
61 Paramyxoviridae and is considered one of the most contagious infectious pathogens 
62 worldwide (Lamb and Parks, 2007). However, due to suboptimal vaccine delivery in 
63 developing countries and increasing cases of vaccination refusals in industrialized areas, 
64 MeV continues to kill around 90’000 people per year (Simons et al., 2012). The related 
65 canine distemper virus (CDV) exhibits high potential to easily cross the species barriers and 
66 was recently associated with severe outbreaks in monkeys (Sakai et al., 2013). Consistent 
67 with this zoonotic capability, CDV also represents an important threat for endangered animal 
68 populations, such as giant pandas in China (Feng et al., 2016; Jin et al., 2017). Although 
69 effective antivirals may support vaccination campaigns and help to contain local epidemics, 
70 no FDA-approved anti-morbilliviral drug is currently available. However, efficacy of a small-
71 molecule inhibitor of the viral polymerase was recently demonstrated in a large animal model 
72 of morbillivirus-mediated pathogenesis (ferrets) when orally administrated at the onset of 
73 viremia (post-exposure treatment protocol) (Krumm et al., 2014). A peptidic fusion inhibitor 
74 was also shown to protect against lethal MeV infections in a cotton rats model, even though, 
75 in that case, prophylactic protocols with intranasal delivery of the antiviral were required, 
76 which certainly challenge clinical feasibility (Mathieu et al., 2015).
77 The morbilliviral cell entry system may define another attractive target for antiviral 
78 drug development. Indeed, in both viruses only one serotype has been described, thereby 
79 highlighting the lack of sufficient plasticity within the two surface glycoproteins to efficiently 
80 escape binding of neutralizing antibodies. Importantly, structural and mechanistic 
81 understanding of the molecular mechanism of cell entry is supportive to successfully achieve 
82 the rationale design and chemical improvements of desired inhibitors. 
83 MeV and CDV cell entry is mediated by the co-operated action of the two tightly 
84 interacting attachment (H) and fusion (F) envelope glycoproteins. Upon H-to-receptor 
85 binding, a cascade of conformational changes occurs, which in turn translates into F 
86 activation at the right time and place (Ader-Ebert et al., 2015; Ader et al., 2012; Apte-
87 Sengupta et al., 2013; Brindley et al., 2012; Herren et al., 2018; Navaratnarajah et al., 2014; 
88 Navaratnarajah et al., 2012; Plattet et al., 2016). This mechanism is thought to lead to the 
89 merging of the viral envelope with the host cell plasma membrane, which is followed by the 
90 formation of a fusion pore and, ultimately, allowing the injection of the genetic information 
91 into the cytosol (Lamb and Parks, 2007; Russell et al., 2001).
92 The F protein of morbilliviruses belongs to class I viral fusion proteins, such as Ebola 
93 virus GP, human immunodeficiency virus GP160 or influenza virus HA. The F protein is first 





























































95 F0 trimerizes and is further cleaved into two covalently-linked subunits F1 and F2. F1 is 
96 composed of an N-terminal hydrophobic fusion peptide, two heptad repeat regions (HRA and 
97 HRB), a long intervening sequence (between both HR domains) potentially encompassing 
98 the H-binding site, a transmembrane domain and a C-terminal cytoplasmic tail (Plattet et al., 
99 2016). Based on the recently determined MeV F protein structure as well as reported crystal 
100 structures of related paramyxovirus and pneumovirus F proteins, it is assumed that F initially 
101 assumes a metastable, prefusion state (Hashiguchi et al., 2018; McLellan et al., 2013; Wong 
102 et al., 2016; Xu et al., 2015; Yin et al., 2006). The ectodomain contains a short stalk (mainly 
103 formed by the assembly of three HRB domains) and a large globular head, which has been 
104 subdivided into three subdomains (DI, DII and DIII). DIII mainly contains the three HRA 
105 regions, which fold compactly at the top of the head, whereas DI and DII constitute the base 
106 of the globular head (Yin et al., 2006). It is assumed that upon H-mediated F-triggering, the 
107 HRB helical bundle (stalk) unwinds, which in turn enables HRA regions to refold into a long 
108 trimeric coiled-coil and to thereby propel the fusion peptides towards the target cell 
109 membrane. The achieved F-conformational state is referred to as the pre-hairpin 
110 intermediate. Then, it is proposed that the three HRB regions swing around the base of the 
111 head and zipper-up along the central coiled-coil HRA to generate a highly stable six-helix 
112 bundle (6HB) structure (Plattet et al., 2016).
113 Although the formation of the 6HB is considered to correlate with membrane merging, 
114 assembly of a four or five-helix bundle may in fact be sufficient to drive spontaneous lipid 
115 mixing. Indeed, insertion of single cysteine substitution at the most membrane-proximal 
116 hydrophobic positions of the MeV F-HRB (stalk) region translated into the assembly of 
117 covalently-linked F-dimers with only moderate impact on membrane fusion activity. Because 
118 the cysteine mutation was introduced into each protomer, we speculated that dimer-of-
119 trimers were generated (Brindley et al., 2014). Such hexameric structures may have involved 
120 two covalently-linked protomers from the same trimer and two covalently-linked protomers 
121 from two adjacent trimers (to balance the stoichiometry of covalent bonds and enable the 
122 assembly of productive prefusion-like hexameric structures). Importantly, strong evidence 
123 was provided to exclude temporary opening of the engineered disulfide bonds to achieve 
124 membrane fusion activity (Brindley et al., 2014). 
125 AS-48 and derivative chemical analogs (e.g. 3G) represent a unique class of small-
126 molecule morbilliviral fusion inhibitors with broad-spectrum activities, but with only moderate 
127 efficacy (low-to-sub micromolar range of 50% inhibitory concentrations) (Plemper et al., 
128 2004; Singethan et al., 2010; Sun et al., 2006). It was previously demonstrated that those 
129 compounds potentially stabilized the prefusion state of MeV and CDV F proteins in turn 
130 preventing productive H-mediated F-activation (Avila et al., 2014; Doyle et al., 2006). The 





























































132 inhibition through prefusion F stabilization by the compound. Indeed, AS-48 docks onto three 
133 hydrophobic pockets locating at the interface between the stalk and head regions 
134 (Hashiguchi et al., 2018); a microdomain that is likely critical for F activation since AS-48-
135 resitance mutations mapped within or around the pocket and displayed either hyperfusogenic 
136 profiles or even turned dependent of AS-48 for their bioactivity (Doyle et al., 2006; Ha et al., 
137 2017; Jurgens et al., 2015; Watanabe et al., 2015; Watanabe et al., 2013).
138 In this study, we aimed at investigating whether the engineering of disulfide bonds at 
139 core hydrophobic positions within the CDV F-stalk region would result in 3G-resitance 
140 profiles. Based on the usage of a cell-to-cell fusion assay, conformation specific anti-F 
141 monoclonal antibodies and low-resolution electron microscopy structural analyses, our data 
142 were suggestive for a primary resistance mechanism mediated by “top-stalk” CDV F cysteine 
143 mutants. These findings highlighted the important role of four CDV F residues (I564, V571, 
144 G572 and L575), all locating at the interface between the head and stalk domain, as 






























































147 2. Materials and Methods
148 2.1. Cell cultures and transfections. Depending on the experiments, the cells used 
149 included Vero cells (ATCC CCL-81) or Vero cells stably expressing canine SLAM (Vero-
150 cSLAM, kindly provided by Yusuke Yanagi, Kyushu University, Japan). Both cell type were 
151 grown in Dulbecco's modified Eagle medium (Gibco, Invitrogen) containing 10% fetal calf 
152 serum (FCS; BioSwissTech) and 1% penicillin-streptomycin at 37°C and 5% CO2. The cells 
153 were transfected with TransIT-LT1 (Mirus) following the manufacturer’s instructions. For 
154 regular cell-cell fusion assays, the extent of fusion induction was recorded by taking pictures 
155 of representative fields of view 24 hours post-transfection. In the indicated experiments, F 
156 and H-expressing Vero-cSLAM cells were treated, 24 hours post-transfection, with 50 mM of 
157 dithiothreitol (DTT) during 30 min, to potentially reactive fusion activity.
158
159 2.2. Construction of expression plasmids. All mutant CDV F protein-expressing plasmids 
160 are based on the pCI plasmid containing a modified version of CDV-F of the A75/17 CDV 
161 strain (Plattet et al., 2007; Plattet et al., 2005). Mutations in the CDV F-expressing DNA 
162 plasmid were introduced using the QuikChange lightning site-directed mutagenesis kit 
163 (Agilent Technologies). Furthermore, all F proteins contained a FLAG-tag inserted within the 
164 ectodomain (Ader et al., 2013).
165
166 2.3. Quantitative fusion assay. Vero cells in a 24-well plate were transfected with 0.5µg of 
167 H protein plasmid, 1µg of variant F protein plasmid and 1µg of the second part of the dual-
168 split reporter plasmid (DPS 8-11) per well. At the same time Vero-cSLAM cells in a 24-well 
169 plate were transfected with 1µg DSP1-7. 24h post transfection the Vero cells expressing the 
170 fusion machinery and DPS 8-11 were detached with 80µl trypsin before adding 235µl DMEM 
171 (with or without the fusion inhibitor 3G) and transferring wells into individual tubes. Vero-
172 cSLAM cells were detached with 80µl Trypsin before adding 235µl of DMEM (with or without 
173 the fusion inhibitor 3G) containing 120µM EnduRen™ Live Cell Substrate (Promega) and 
174 pooling these Vero-cSLAM. 300µl Vero-cSLAM cells were then distributed to the tubes 
175 containing the Vero cells. The mixed cells were distributed into four wells of a white 96-well 
176 plate per mutant. The plate was centrifuged 5min at 200g and then placed in the Cytation 5 
177 Cell Imaging Multi-Mode Reader (BioTek). To quantify the luminescence intensity read-out, 
178 the maximum reached during the measurement was divided by the time to reach the 
179 maximum for every mutant. Thereby an indication of kinetics was gained. 
180
181 2.4. Immunofluorescence staining and flow cytometry. Vero cells were transfected with 1 
182 µg of various F-expressing DNA plasmids. One day post transfection, unfixed and 





























































184 subsequently stained with the various antibodies (1:1000) for 1 hour at 4°C. The anti-CDV F 
185 mAbs 4941 and 3633 or anti-FLAG mAb (Sigma Aldrich) were employed. This was followed 
186 by washes with cold PBS and incubation of the cells with Alexa-fluor 488-conjugated 
187 secondary antibody (1:500) for 1 hour at 4°C. Cells were subsequently washed 2 times with 
188 cold PBS and consequently detached from the wells by adding PBS-EDTA (50 µM) 20 min at 
189 37°C. The mean fluorescence intensity (MFI) of 10’000 cells was then measured by using a 
190 BD LSRII flow cytometer (Becton Dickinson). When indicated, brief heat shocks (5 min) at 
191 different temperatures (37 and 65°C) were performed prior to the staining.
192
193 2.5. Surface immunoprecipitation. Vero cells in a 6-well plate were transfected with 3 µg of 
194 F-wt (and derivate mutants)-expressing plasmid DNA per well. 24 hours post transfection the 
195 medium was changed to OptiMEM containing 1:2000 anti-FLAG mAb (Sigma Aldrich; 
196 SAB4200071) and incubated at 4°C for 1h. Cells were washed with PBS and then incubated 
197 with lysis buffer (10 mM Tris-HCl, pH7.4, 150 mM NaCl, 1% deoxycholate, 1% Triton X-100, 
198 0.1% sodium dodecyl sulfate (SDS)) containing protease inhibitor (Roche, complete mix)) at 
199 4°C. Cell lysates were transferred into tubes and centrifuged at 4°C with 16000g for 30min. 
200 Supernatants were transferred into new tubes and 15 µl of Dynabeads™ Protein G for 
201 Immunoprecipitation (Invitrogen) were added. The tubes were incubated 4 hours at 4°C on a 
202 rotating wheel before the beads were washed with PBS containing 0.05% Tween 40 (Merck). 
203 The beads were then boiled at 95°C in Laemmli buffer without reducing agent and proteins 
204 subjected to Western blot analyses.
205
206 2.6. Western blotting. Western blots were performed as previously described (Plattet et al., 
207 2009; Wiener et al., 2007). Samples were fractionated on NuPAGETM 3-8% Tris-Acetate Mini 
208 gels (ThermoFisher Scientific) under nonreducing conditions. Separated proteins were 
209 transferred to nitrocellulose membranes by electroblotting. The membranes were then 
210 incubated with the polyclonal anti-CDV-F antibody (1:1000) (Cherpillod et al., 1999). 
211 Following incubation with a peroxidase-conjugated secondary antibody, the membranes 
212 were subjected to 1-StepTM TMB (3,3',5,5'-tetramethylbenzidine)-blotting substrate solution 
213 (ThermoFisher Scientific), according to the manufacturer's instructions.
214
215 2.7. Protein production, purification and negative-stain electron microscopy. The 
216 previously described solF-GCNt-expressing DNA plasmid was used as template to produce 
217 solF-GCNt-V571C (Ader et al., 2013). Both plasmids were sent to a protein production core 
218 facility (PECTF, Dr. D. Hacker, EPFL, Switzerland). From 1L of supernatants harvested after 
219 7 days of protein expression in HEK-293T cells grown in suspension, we usually reached 





























































221 Since both recombinant proteins harbored a C-terminal HA-tag, affinity purifications were 
222 performed using a commercially available agarose beads anti-HA mAb (Covance) and HA 
223 peptides for elution. For all four samples, i.e., solF-GCNt and solF-GCNt-V571C in the 
224 presence and absence of the inhibitor 3G, 4 µl (~30 µg/ml) were adsorbed for 5 s to 
225 parlodion carbon-coated copper grids rendered hydrophilic by glow discharge at low 
226 pressure in air. Grids were washed with three drops of double-distilled water and stained with 
227 2 drops of 0.75% uranyl formate. Images were recorded with a FEI Tecnai Spirit BioTwin 
228 transmission electron microscope operated at 80 kV and equipped with a FEI Eagle CCD 






























































231 3.1. CDV F cysteine mutants assemble into covalently-linked dimers exhibiting 
232 prefusion-like conformations. We previously reported that introducing a cysteine residue at 
233 the most membrane-proximal hydrophobic positions of the measles virus F-stalk domain led 
234 to the assembly of covalently-linked dimers with moderate functional impact (presumably 
235 through the generation of “dimer-of-trimers”) (Brindley et al., 2014). To determine whether 
236 engineered disulfide bridges within the CDV F-stalk domain would similarly translate into 
237 functional structures and whether such complexes would additionally gain resistance to the 
238 fusion inhibitor 3G (an AS-48 chemical analog), we inserted single cysteine amino acid at 
239 every predicted core position of the F-stalk region (Fig. 1A). It is worth to note that all protein 
240 variants also harbored a FLAG-tag in the ectodomain at a previously reported location 
241 demonstrated to have only minor impacts on F-refolding and membrane fusion-triggering 
242 (Ader et al., 2013). The generated panel of F variants was submitted to a series of 
243 established bioassays to determine surface expression, conformational state, membrane 
244 fusion activity and oligomerization propensity.
245 The expression and conformational states of standard and mutant F proteins at the 
246 cell surface of transfected Vero cells were probed by immunofluorescence and flow 
247 cytometric analysis using three previously identified monoclonal antibodies (mAb): an anti-
248 FLAG mAb (recognizing F protein in a conformation-independent manner), an anti-Pre mAb 
249 (recognizing the prefusion state) and an anti-Trig mAb (recognizing the postfusion state) 
250 (Ader et al., 2013). With the exception of the F-L582C variant, which displayed some 
251 intracellular transport-deficiency, all other F-mutants were efficiently expressed at the cell 
252 surface (Fig. 1B). Most importantly, introducing a single cysteine at every hydrophobic core 
253 positions of the putative three-helical bundle of the CDV F-stalk domain did not alter the 
254 conformational state of the trimer: all F proteins readily folded into prefusion-like states (Fig. 
255 1B). 
256 To determine whether the CDV F cysteine variants formed the expected disulfide 
257 bridges (generating covalently-linked F-dimers), the different proteins were expressed in 
258 Vero cells and cell surface antigenic material was immunoprecipitated using an anti-FLAG 
259 mAb. Proteins were then submitted to Western blot analyses performed under non-reducing 
260 conditions. Consistent with our previous data obtained with similar MeV F variants (Brindley 
261 et al., 2014), all mutated CDV F proteins exhibited obvious covalently-linked dimeric 
262 populations. In sharp contrast, wild-type F proteins exclusively displayed the expected 
263 monomeric (F0) population (Fig. 2). The profile of migration of CDV F mutants harboring the 
264 combination of L596C and V599C (“double”) or I589C, L596C and V599C (“triple”) cysteine 
265 substitutions were also investigated. Interestingly, while the “double” F mutant mostly 





























































267 higher oligomers (Fig. 2). As control, we also mutated residues I564 and G572 of CDV F into 
268 cysteines (referred to as the “twin” mutant). It was reported that substituting the two 
269 homologous positions of MeV F proteins resulted in inter-monomeric disulfide bonds 
270 formation at the interface of the stalk and head domain, thereby generating covalent 
271 prefusion F-trimers characterized biochemically and by dithiothreitol (DTT)-dependent 
272 reversible fusion activity profiles (Lee et al., 2007). When the CDV F-I564C/G572C “twin” 
273 cysteine mutant was subjected to Western blot analysis performed under similar conditions, 
274 a covalently-linked trimeric population was indeed readily stabilized (Fig. 2). 
275 Collectively, these data demonstrated that the F proteins carrying cysteines at every 
276 core position of the stalk domain readily formed covalently-linked dimers, which were 
277 properly transported to the cell surface in prefusion-like conformations.
278
279 3.2. “Top-stalk” CDV F cysteine mutants exhibit resistance to 3G. We next investigated 
280 whether the F cysteine mutants preserved proper bioactivity and whether those mutants 
281 would additionally remain sensitive towards the small-molecule fusion inhibitor compound 
282 3G. Membrane fusion activity of the diverse F cysteine variants was thus investigated both 
283 qualitatively and quantitatively in presence and absence of the inhibitor, using an adapted 
284 protocol recently described (Herren et al., 2018).
285  In absence of 3G and compared to F-wt, “top-stalk” F-L575C, A578C and S582C 
286 mutants exhibited only slight impairments in membrane fusion triggering (Fig. 3A and B), 
287 whereas F-L571C featured about 40% activity. Conversely, “bottom-stalk” F variants 
288 harboring cysteine substitutions at position 585, 589 and 592 displayed severe functional 
289 defects (Fig. 3A and B). However, the two most membrane-proximal F cysteine mutants (F-
290 L596C and F-V599C) exhibited substantial bioactivity. Noteworthy, the “double” and “triple” F 
291 mutants were strongly impaired in promoting membrane fusion (Fig. 3A and B). Remarkably, 
292 in presence of high concentration of 3G (75 µM), CDV F-V571C and F-L575C displayed 
293 resistance to the fusion inhibitor, whereas all other mutants remained strongly sensitive, 
294 consistent with the profile of inhibition observed in case of F-wt (Fig. 3A and B). 
295 To demonstrate that the engineered disulfide bridges contributed to the functional 
296 defects of some “bottom-stalk” F cysteine mutants, F-expressing cells were treated 30 min 
297 with a mild concentration of DTT (50 mM) to potentially reduce the covalent bonds and 
298 eventually restore membrane fusion induction. In this series of experiments, we selected the 
299 F cysteine variants S592C and “triple”, because exhibiting severe functional impairments. As 
300 positive control, we employed the above described “twin” F cysteine variant. In addition, upon 
301 DTT treatment, cells were treated (or not) with 3G to determine the sensitivity of the selected 
302 F variants to the fusion inhibitor. Strikingly, while both “bottom-stalk” F cysteine mutants 





























































304 entirely sensitive to the fusion inhibitor compound (Fig. 4). In sharp contrast, the “twin” 
305 mutant (I564C/G572C), which was indeed reactivated upon DTT treatment, displayed some 
306 resistance to 3G, since fusion activity could be recorded (Fig. 4).
307 Overall, these data demonstrated that CDV F proteins carrying cysteine substitutions 
308 at positions 571, 575, 564 and 572 (the two latter in combination), all locating at the top of 
309 the stalk region, displayed resistance to 3G. Conversely, “bottom-stalk” F cysteine mutants 
310 remained fully sensitive to the fusion inhibitor.
311
312 3.3. “Top-stalk” CDV F cysteine mutants escaped 3G-mediated stabilization upon heat 
313 shock. The prefusion MeV F crystal structure in complex with AS-48 highlighted the 
314 interacting residues (Hashiguchi et al., 2018). Previously identified critical residues of 
315 resistance mutations against AS-48 (e.g. F-N462K) (Doyle et al., 2006) indeed locate in the 
316 binding pocket (Hashiguchi et al., 2018). A structurally-diverse MeV F inhibitor (fusion 
317 inhibitor peptide [FIP]; (Richardson et al., 1980)) was suggested (Ha et al., 2017), and now 
318 proven (Hashiguchi et al., 2018), to dock at the identical microdomain. Most FIP-resistance 
319 mutations (which also conferred resistance to AS-48) were indeed part of the hydrophobic 
320 pocket binding site (e.g. I452, D458, V459, N462 and G464) (Ha et al., 2017). Interestingly, 
321 CDV F residues V571, L575, I564 and G572 putatively locate in close proximity to the 
322 homologous residues of those MeV F amino acids, which therefore suggest a primary 
323 resistance mechanism.
324 We previously developed an assay, which enabled us to identify the stabilizing impact 
325 of 3G on prefusion F trimers. The assay relied on binding of F conformation-specific mAbs 
326 after heat shock treatment, to artificially trigger refolding. This strategy enabled us to 
327 accurately assess the “temperature of refolding”, thus indirectly informing about F trimers’ 
328 intrinsic stability. Strikingly, if 3G docked onto prefusion F complexes, the temperature of 
329 refolding was increased by around 5-10°C (Avila et al., 2014). To indirectly determine 
330 whether 3G was still able to bind and stabilize the prefusion conformation of the designed F 
331 cysteine mutants, we adapted this assay by employing two mAbs: anti-Pre (recognizing the 
332 prefusion state) and anti-FLAG (recognizing the FLAG-tag and indicating cell surface 
333 expression). The impact of 3G on prefusion F states was thus determined by calculating the 
334 ratio between the binding capacities of the anti-Pre and anti-FLAG mAbs (determined by flow 
335 cytometry). Such experiments were conducted either at physiological temperature (37°C) or 
336 after a brief heat shock (5min, 65°C) in presence or absence of the fusion inhibitor.
337 At 37°C, selected “top-stalk” (V571C and L578C) and “bottom-stalk” (L596C and 
338 V599C) F protein variants exhibited very similar proportion of prefusion states trimers in the 
339 presence or absence of 3G (Fig. 5A). When data were normalized to conditions performed in 





























































341 treated cells and upon brief heat shock at 65°C, a considerable amount of prefusion F trimers 
342 could still be detected in case of F-wt and the two “bottom-stalk” F cysteine variants (L596C 
343 and F-V599C) as compared to “top-stalk” mutants (Fig. 5C). The differences became even 
344 more apparent when data were normalized to conditions performed in the absence of the 
345 drug (Fig. 5D). Interestingly, the “twin” mutant displayed an intermediate phenotype; 
346 although 3G could still impact the prefusion state to some extent (Fig. 5C), the stabilizing 
347 effect was clearly less potent as compared to the one exerted on mutants F-L596C and F-
348 V599C (Fig. 5D). Note also that prefusion states of tested “bottom and top-stalk” F cysteines 
349 mutants were slightly destabilized as compared to F-wt, since, in absence of 3G, F-wt 
350 seemed to be less temperature-sensitive as seen after a brief heat shock (Fig. 5C). 
351 Conversely, in absence of the drug, the “twin” mutant featured wt-like stability (Fig. 5C).
352 Taken together, our data demonstrated that the drug-resistant “top-stalk” CDV F 
353 cysteine mutant did not exhibit 3G-mediated stabilization of prefusion states (F-V571C and 
354 F-L575C), or only to limited extent (“twin” F-I564C/G572C variant). This suggested that 
355 resistance resulted from lack of efficient docking of the compound on those mutated 
356 prefusion F-structures. Since CDV F amino acids I564, V571, G572 and L575 are all 
357 potentially part of the hydrophobic pocket, these findings revealed that prefusion CDV and 
358 MeV F trimers are likely sharing substantial structural similarities. It is therefore expected that 
359 3G presumably docks onto the same pocket as AS-48 did on prefusion MeV F structures 
360 (Hashiguchi et al., 2018).
361
362 3.4. Unmodified soluble F proteins preferentially display a “prefusion-like” state in 
363 presence of 3G. To provide more direct evidence that 3G may indeed exert a stabilization 
364 effect on prefusion CDV F trimers, we expressed a previously reported soluble F construct 
365 (solF) in HEK-293T cells (Ader et al., 2013). The latter was engineered to carry a trimeric 
366 GCN4 motif (GCNt) in place of the transmembrane and cytoplasmic tail domains (solF-
367 GCNt). In parallel, we inserted the V571C mutation into the soluble protein (solF-GCNt-
368 V571C) and expressed it under similar conditions. After affinity purification, both recombinant 
369 soluble proteins were submitted to SDS-PAGE migration performed under non-reducing 
370 conditions and were subsequently revealed by Coomassie staining. As expected from our 
371 previous analysis, while solF-GCNt exclusively migrated as a monomeric population, solF-
372 GCNt-V571C displayed both monomers and dimers, which corroborated the results obtained 
373 with their full-length membrane-anchored counterparts (Fig. 6A). 
374 Next, both recombinant soluble proteins were expressed in the presence or absence 
375 of 3G (75 µM) and purified proteins were analyzed by negative-stain electron microscopy. 
376 Interestingly, in the absence of the compound, both soluble proteins exhibited a mixed 





























































378 like elongated conformations (presumably postfusion states) (Fig. 6B and C). This indicated 
379 that, despite soluble F proteins harboring the prefusion-stabilizing trimerization motif, 
380 spontaneous refolding into postfusion states did occur in a considerable number of F-trimers. 
381 Remarkably, in the presence of 3G, a substantial number of solF-GCNt displayed the 
382 prefusion state, whereas solF-GCNt-V571C exhibited unaltered mixed conformational 
383 populations (Fig. 6Band C). These findings not only validated that 3G had no impact on 
384 prefusion states of “top-stalk” F cysteine mutants, but also that metastable conformations of 






























































387 Molecular understanding of the mode-of-action and associated potential resistance 
388 mechanisms of a given antiviral is supportive to its usage in clinic. It was reported that the 
389 small-molecule fusion blocker AS-48 class compounds may exert their inhibitory function by 
390 stabilizing prefusion morbilliviral F structures (Avila et al., 2014; Doyle et al., 2006). The 
391 recently determined prefusion MeV F structure in complex with AS-48 demonstrated that the 
392 fusion inhibitor bound to three hydrophobic pocket microdomains located at the interface of 
393 the head and stalk domains (Fig. 7A; CDV F model) (Hashiguchi et al., 2018). Since 
394 mutations within and around this region led to hyperfusogenic F profiles, a functional role of 
395 the head-stalk interface in the F-triggering/refolding process was suggested (Doyle et al., 
396 2006; Jurgens et al., 2015; Lee et al., 2007; Watanabe et al., 2015; Watanabe et al., 2013). 
397 Additionally, since some of those AS-48 resistant mutants exhibited intracellular transport-
398 deficiency in the absence of the compound, which was restored in its presence, a stabilizing 
399 role of the inhibitor on prefusion MeV F complexes was inferred (Doyle et al., 2006). Here, 
400 we conducted comprehensive mechanistic and low-resolution structural analyses to 
401 determine whether engineered disulfide bridges within the CDV F-stalk domain may provide 
402 resistance profiles to 3G, an AS-48 chemical analog compound.
403 We recently demonstrated that cysteine substitutions performed in the MeV F-stalk 
404 translated into membrane fusion triggering-competent, covalently-linked, F dimers. Such 
405 productive F complexes were hypothesized to result from the assembly of putative dimer-of-
406 trimers (Brindley et al., 2014). Considering that the base of the globular head is quite large as 
407 compared to the compact helical bundle stalk region, structural flexibility within at least one 
408 monomer of two neighboring F trimers must be considerable in order to allow, stalk-
409 dependent, inter-trimers disulfide bond formation. We thus employed this approach to 
410 rationally engineer conformational distortions within the CDV F-stalk region and potentially 
411 disturb the binding efficacy of the drug.
412 Consistent with data obtained in the context of MeV F (Brindley et al., 2014), 
413 introducing cysteine residues at every hydrophobic core positions within the three-helix 
414 bundle stalk domain of prefusion CDV F led to the generation of covalently-linked dimeric 
415 complexes. Such complexes may fold into covalently-linked dimer-of-trimers, which would 
416 indeed require a certain degree of structural freedom within the F-stalk region to achieve 
417 productive prefusion architectures. Based on the findings collected in this study, we further 
418 hypothesize that structural flexibility within the morbilliviral F-stalk domain may potentially 
419 occur only locally. Local structural flexibility within the stalk may preserve the membrane-
420 distal 3G binding sites unaltered when disulfide bonds are engineered membrane-proximal. 
421 Conversely, introducing supplementary covalent bonds at the top of the stalk may directly (or 





























































423 Three lines of evidence support our model. Firstly, mutations conferring resistance to 
424 the morbillivirus fusion inhibitor Z-D-Phe-L-Phe-Gly peptide (FIP) were recently mapped to 
425 the structural transition between the globular head and the stalk domain (Ha et al., 2017). 
426 Because most of the FIP-resistance mutations were demonstrated to also provide resistance 
427 to AS-48, both fusion inhibitors were suggested to bind to the same microdomain on 
428 prefusion MeV F structures (Ha et al., 2017). Interestingly, in MeV F/inhibitor co-crystal 
429 structures, most of the resistance mutations were located at the rim and/or at the bottom of 
430 the deep hydrophobic pocket shown to accommodate the benzene group of AS-48 and FIP 
431 (Fig. 7B and C) (Hashiguchi et al., 2018). Taken together, since the MeV F homologous 
432 amino acids to CDV F residues I564, V571, G572 and L575 (“top-stalk” mutants), all map 
433 within the AS-48 binding site, it is not unexpected that 3G would bind to same microdomains 
434 on prefusion CDV F structures.
435 Secondly, our data provided clear evidence that “top-stalk” CDV F cysteine variants 
436 (F-V571C and F-L575C) gained resistance to 3G, whereas “bottom-stalk” variants remained 
437 sensitive to the drug. In addition, drug-resistance phenotypes were also recorded with the 
438 “twin” F cysteine mutant, which harbors two mutations locating at the top of the stalk and at 
439 the base of the head domain. These data highlighted the intriguing notion that resistance or 
440 sensitivity to 3G relied on the position of the covalent bond engineered within the CDV F-
441 stalk region. However, whether the 3G-resistance profiles of ”top-stalk”  mutants resulted 
442 from lack of hydrophobicity within the binding site, direct disruption of the pocket, or an 
443 overall F structure incompatible to 3G binding (long-range effect) warrants further 
444 investigations.
445 Thirdly, we demonstrated that the prefusion conformations of “bottom-stalk” F 
446 cysteine mutants gained resistance to heat shock treatments in presence of the drug. 
447 Conversely, prefusion states of “top-stalk” CDV F cysteine variants remained sensitive to 
448 heat treatments regardless of the presence or absence of the fusion inhibitor. It is worth to 
449 note that 3G could still stabilize the “twin” F mutants to some extent. However, the impact 
450 was substantially less potent than the effect exerted on other “bottom-stalk” F mutants, which 
451 suggested a partial drug-resistance profile of the “twin” mutant. These data therefore argued 
452 for the inability of the drug to efficiently bind to those “top-stalk” CDV F mutated trimers and 
453 consequently highlighted a potential primary site resistance mechanism (direct or indirect). 
454 Interestingly, in a previous study, we identified F mutants harboring substitutions locating 
455 within a microdomain at the center of the F globular head domain, and those mutated F 
456 proteins similarly displayed resistance to 3G. However, in contrast the “top-stalk” cysteine F 
457 mutants designed in this study, the “central pocket” F mutants remained still strongly 
458 stabilized by the compound, which rather provided evidence for a secondary resistance 





























































460 Low-resolution electron microscopy experiments were additionally strongly suggestive 
461 for a stabilizing impact of 3G on prefusion F trimers and for a primary site resistance 
462 mechanism exhibited by “top-stalk” F cysteine mutants. Indeed, solF-GCNt exhibited a mixed 
463 population with roughly 50% of F proteins preserving the prefusion state, whereas the other 
464 50% spontaneously refolded into the postfusion state. Although this clearly illustrated that 
465 GCNt trimerization motifs were not sufficient to completely maintain these F trimers in the 
466 prefusion conformation, it however underlined the stabilizing impact of 3G. In presence of the 
467 fusion inhibitor, mixed F structures switched to a much more homogenous F population, 
468 characterized by the almost exclusive presence of prefusion state solF-GCNt. Even though 
469 prefusion MeV F-trimers are likely equally stabilized by AS-48, the phenotype could not be 
470 monitored in high-resolution structural analyses, since the apo-state was already stabilized 
471 through the engineering of disulfide bonds within the bottom of the stalk domain (Hashiguchi 
472 et al., 2018). Finally, our structural analyses unambiguously indicated that 3G lost its 
473 prefusion-stabilizing impact when tested on a soluble “top-stalk” F cysteine variant (solF-
474 GCNt-V571C). Overall these data provided further evidence for the mode-of-action of 3G-
475 mediated fusion inhibition and associated mechanisms of resistance. 
476 To date, high-resolution structures of pneumovirus and paramyxovirus prefusion F 
477 trimers in complex with structurally diverse fusion inhibitory compounds are available for 
478 respiratory syncytial virus (RSV) and measles virus (Battles et al., 2016; Hashiguchi et al., 
479 2018). Remarkably, in RSV F crystal structures, all chemical compounds bound to a 
480 threefold-axis internal central pocket locating at the base of the globular head domain. Thus, 
481 different binding sites were determined between fusion inhibitors acting on RSV or MeV F 
482 proteins. Considering the high mutational rates of polymerase of envelope RNA viruses and 
483 the demonstrated high propensity of emergence of drug-resistant viral variants, as well as 
484 structural similarities between RSV and MeV F trimers, it may be attractive to rationally 
485 develop second generation of RSV F inhibitors potentially binding to pocket microdomains 
486 mimicking those targeted by AS-48 and FIP in MeV F.
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661 Figure 1. Characterization of CDV F-mutants harboring cysteine substitution at every 
662 hydrophobic core position of the putative helical bundle stalk region. (A) Side view of 
663 prefusion CDV F-trimer, which consists of a globular head and stalk domains. The model 
664 was generated from the related PIV5 prefusion F-structure (PDB code: 2B9B). The 3-helix 
665 bundle stalk domain and derived 7-mer core hydrophobic positions (“a” and “d”) are 
666 highlighted on the right side. The three monomers are color-coded in yellow, cyan and red. 
667 pm: plasma membrane. (B) Conformational probing of surface-exposed F proteins was 
668 performed using three different mAbs: anti-FLAG (conformation-independent; grey bars), 
669 anti-Pre (prefusion-specific; green bars) and anti-Trig (postfusion-specific; red bars). Upon 
670 addition of Alexa-fluor-conjugated secondary antibody, F-expressing cells were detached 
671 and submitted to flow cytometry analyses to record quantitative data. Means and standard 
672 deviations of data from three independent experiments performed in triplicates are shown. 
673 Double: CDV F-L596C/V599C; triple: CDV F-I589C/L596C/V599C.
674
675 Figure 2. Biochemical analyses of the panel of CDV F cysteine mutants. To investigate 
676 oligomeric profiles, Vero cells were transfected with the various F-expressing plasmids. 24 
677 hours post-transfections, cell surface F-antigenic materials were immunoprecipitated and 
678 submitted to Western blot analyses performed under nonreducing conditions. M: F-
679 monomers; D: F-dimers; T: F-trimers; HO: F-high order oligomers. Double: CDV F-
680 L596C/V599C; triple: CDV F-I589C/L596C/V599C; twin: CDV F-I564C/G572C.
681
682 Figure 3. Top-stalk CDV F cysteine mutants readily escape 3G-mediated fusion 
683 inhibition. (A) F proteins were co-expressed with H-proteins in Vero-cSLAM cells and 
684 treated, or not, with 75 µM of 3G. Assessment of cell-cell fusion induction was performed by 
685 taking pictures of representative fields of view 24 hours post-transfection. (B) Quantitative 
686 assessment of cell-cell fusion induction in presence or absence of 75 µM of 3G. Means ± 
687 standard deviations of data from two independent experiments performed in triplicates are 
688 shown. Double: CDV F-L596C/V599C; triple: CDV F-I589C/L596C/V599C.
689
690 Figure 4. Impact of the engineered disulfide bonds on non-functional F cysteine 
691 mutants. The cell-cell fusion capacity of the “twin” (I564C/G572C), “triple” 
692 (I589C/L596C/V599C) and S592C F cysteine mutants were analyzed by regular cell-cell 





























































694 profiles of the various F proteins, Vero-cSLAM cells were treated 30 min, 24 hours post-
695 transfections, with a mild concentration (50 mM) of dithiothreitol  (+DTT), or left untreated (-
696 DTT). In the indicated conditions, 3G (75 µM) was added post DTT-treatments.  
697
698 Figure 5. Heat shock-resistance profiles of perfusion F conformations in presence or 
699 absence of the fusion inhibitor compound. (A-B) Selected F proteins were expressed in 
700 Vero cells for 24 hours. Cells were then subjected to brief heat shocks (5 min) at 37°C (A) or 
701 65°C (B) in the presence or absence of 75 µM of 3G. Conformational probing of surface-
702 exposed F proteins was performed using two different mAbs: anti-FLAG (conformation-
703 independent) and anti-Pre (prefusion-specific). Upon addition of Alexa-fluor-conjugated 
704 secondary antibody, F-expressing cells were detached and submitted to flow cytometry 
705 analyses to record quantitative data. (C-D) For each F-protein, values obtained in the 
706 presence of 3G (+3G) were normalized to values obtained in the absence of the drug (-3G) 
707 and set to 1. Means ± standard deviations of data from three independent experiments 
708 performed in duplicates are shown.
709
710 Figure 6. Biochemical and negative stain electron microscopy analyses of purified 
711 solF-GCNt and solF-GCNt-V571C in the absence and presence of the inhibitor 3G. (A) 
712 Affinity-purified solF proteins were separated by SDS-PAGE migration performed under 
713 nonreducing conditions and were revealed by Coomassie staining. M: F-monomers; D: F-
714 dimers. (B) Electron micrographs of negatively-stained solF-GCNt and solF-GCNt-V571C in 
715 the absence or presence of the fusion inhibitor 3G (75 µM). Only obvious assignable solF-
716 GCNt and solF-GCNt-V571C proteins in the prefusion and postfusion states are highlighted 
717 in yellow and green, respectively. The scale bars represent 100 nm. (C) To collect semi-
718 quantitative data, single F particles in prefusion or postfusion states were counted. Means ± 
719 standard deviations of data from several fields of views are shown. An unpaired two-tailed t 
720 test was performed to assess significant differences compared to wild-type (*, p-value 
721 ≤0.0001)
722
723 Figure 7. Pocket microdomain in CDV F-trimers potentially accommodating the 3G 
724 fusion inhibitor compound and associated resistance mutations. (A) Bottom view of 
725 prefusion CDV F-trimer with the three potential 3G-binding sites color-coded in blue (model 
726 generated from the MeV F prefusion state in the absence of inhibitory compounds (PDB 





























































728 with AS-48 in MeV F prefusion state are highlighted in blue (B). Amino acids within the deep 
729 hydrophobic pocket microdomain that conferred resistance to morbilliviral inhibitors are 
730 shown in red (resistance to AS-48) and cyan (resistance to AS-48 (for MeV F proteins) and 
731 3G (for CDV F proteins)) (C).
732
733 Figure 8. Potential model of covalently-linked F dimer-of-trimers folding and 
734 associated mechanism of resistance to a fusion inhibitor (3G). F complexes in prefusion 
735 conformations are represented. (A) “Top-stalk” and “bottom-stalk” residues V571 and V599, 
736 respectively, are shown in red (left side). The putative binding site of 3G is highlighted with 
737 three green transparent circles (right side). (B) Model of arrangement of “top-stalk” and 
738 “bottom-stalk” covalently-linked dimer-of-trimers. The engineered disulfide bonds are shown 
739 in cyan. Residues V571 and V599 are color-coded in red. “Top-stalk” F complexes display 
740 disturbed 3G binding site (red transparent circles; left side), whereas “bottom-stalk” F 
741 structures feature intact 3G binding sites (green transparent circles). Pm: plasma membrane.
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